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Bullwhip and mini-bullwhip cells are unconventional types of retinal neurons that utilize the neuropeptides glucagon, glucagon-like peptide 1
(GLP1) and substance P. These cells have been implicated in regulating the proliferation of neural progenitors in the circumferential marginal zone
(CMZ) of the chicken retina. The purpose of this study was to investigate the roles of the bullwhip cells in regulating ocular size and shape. We
found that intravitreal delivery of colchicine at postnatal day 7 destroys the vast majority (∼98%) of the bullwhip and mini-bullwhip cells and their
peptidergic terminals that are concentrated in the CMZ near the equator of the eye. Interestingly, colchicine-treatment resulted in excessive ocular
growth that involved the expansion of equatorial diameter, but not axial length. Intraocular injections of glucagon completely prevented the
equatorial expansion that occurs with colchicine-treatment. In eyes with undamaged retinas, exogenous glucagon suppressed equatorial eye growth,
whereas glucagon receptor antagonists caused excessive equatorial growth. Furthermore, visual stimuli that increase or decrease rates of ocular
growth caused a down- or up-regulation, respectively, of the immediate early gene Egr1 in the bullwhip cells; indicating that the activity of the
bullwhip cells is regulated by growth-guiding visual cues. We found that the glucagon receptor was expressed by cells in the fibrous and
cartilaginous sclera in equatorial regions of the eye. Taken together, these findings suggest that glucagon peptide released from the terminals of the
bullwhip and mini-bullwhip cells regulates the growth of the equatorial sclera in a vision-dependent manner. Although the bullwhip and mini-
bullwhip cells are not abundant, less than 1000 cells per retina, their influence on the development of the eye is substantial and includes vision-
guided ocular growth.
© 2008 Elsevier Inc. All rights reserved.Keywords: Retina; Glucagon; Eye growth; NeuronsIntroduction
Achieving proper organ size is a fundamental process in
developmental biology. For example, the eye must grow to a
proper size to achieve clear vision. The combined refractive
power of the lens and cornea must be precisely matched to axial
length and equatorial circumference so that images are focused
directly on the retina. If the eye grows too little (hyperopia; far-
sightedness) or too much (myopia; near-sightedness) the images
that are projected onto the retina tend to be blurred and visual
acuity is poor. The overall growth of the eye is a function of the
sclera, the connective-tissue sheath of the eye. Most vertebrates,
including humans are born hyperopic, with their eyes too small⁎ Corresponding author. Fax: +1 614 688 8742.
E-mail address: fischer.412@osu.edu (A.J. Fischer).
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doi:10.1016/j.ydbio.2008.02.023(reviewed by Rada et al., 2006). However, as development
proceeds, growth occurs so that the size and shape of the eye are
precisely matched to the combined refractive power of the lens
and cornea; this process is referred to as emmetropization (Rada
et al., 2006; Wallman and Winawer, 2004). Visual experience is
required to guide and “fine-tune” the growth of the eye, which
requires retinal detection of image-blur (Wallman and Winawer,
2004). The neurons that detect image-blur and influence scleral
growth remain unknown in the human retina, but may have
been identified in the chicken. Glucagon-expressing amacrine
cells (GACs) in the chicken retina are known to respond
selectively to visual stimuli that slow or accelerate ocular
growth by up- or down-regulating, respectively, the expression
of the immediate early gene Egr1 (Fischer et al., 1999a). In
addition, recent reports have demonstrated that intraocular
injections of glucagon suppress the excessive axial ocular
197A.J. Fischer et al. / Developmental Biology 317 (2008) 196–212growth that results from form-deprivation or divergent lens-
wear (Feldkaemper and Schaeffel, 2002; Vessey et al., 2005a,b).
These studies have suggested that the GACs regulate the axial
growth of the eye, but definitive studies are still required to
demonstrate unambiguously that these cells are directly res-
ponsible for regulating eye growth.
In some classes of vertebrates the growth of the sclera is
somehow coordinated with the growth of the retina. The post-
embryonic growth of the retina is the function of a zone of stem
cells that is located at the peripheral edge of the retina. Retinal
stem cells have been characterized in many different species of
vertebrates (reviewed by Del Rio-Tsonis and Tsonis, 2003;
Fischer, 2005; Otteson and Hitchcock, 2003; Raymond and
Hitchcock, 1997, 2000; Reh and Levine, 1998). In the eyes of
cold-blooded vertebrates, it has been known for several decades
that retinal neurogenesis persists throughout the life of the
animal and arises from stem cells that are found at the peripheral
edge of the retina in the circumferential marginal zone (CMZ).
In recent years, retinal stem cells have been identified in the
postnatal chicken eye in the CMZ (Fischer et al., 2002; Fischer
and Reh, 2000) and further anterior in the non-pigmented
epithelium of the ciliary body (Fischer and Reh, 2003). Secreted
growth factors have been shown to influence the proliferation of
progenitors in the chicken CMZ. Factors that stimulate the
proliferation of CMZ progenitors include insulin, insulin-like
growth factor I (IGF-I), epidermal growth factor (EGF) (Fischer
et al., 2002; Fischer and Reh, 2000) and Sonic Hedgehog
(Moshiri et al., 2005). Conversely, glucagon and glucagon-like
peptide 1 (GLP1) suppress the proliferation of progenitors in the
CMZ (Fischer et al., 2005). Neurites containing glucagon,
GLP1 and substance P are densely clustered within the CMZ at
the peripheral edge of the retina (Fischer et al., 2005, 2006). The
glucagon/substance P-immunoreactive (-IR) neurites that are
ramified in the CMZ originate from unusual types of axon-
forming neurons that have been termed bullwhip and mini-
bullwhip cells (Ehrlich et al., 1987; Fischer et al., 2006). The
bullwhip cells have large cell bodies that are located among the
amacrine cells in the proximal inner nuclear layer (INL). The
bullwhip cells are found only in ventral regions of the retina,
whereas the mini-bullwhip cells (a smaller version of the
bullwhip cells) are found only in dorsal regions of the retina.
There are only about 240 bullwhip cells and 600 mini-bullwhip
cells per retina, and these cells are distinctly different from other
types of retinal cells (Fischer et al., 2005, 2006). It has been
proposed that the bullwhip and mini-bullwhip cells convey
visual information to the CMZ to control the addition of newly
generated cells to the edge of the retina (Fischer et al., 2005).
This control is mediated by neuropeptides, glucagon and GLP1,
that act in opposition to insulin (or insulin-like growth factors)
to regulate precisely the proliferation of retinal progenitors
(Fischer et al., 2005).
Here we report that the ablation of the bullwhip and mini-
bullwhip cells, and their terminals at the peripheral edge of the
retina, results in excessive growth around the equator of the eye,
whereas growth along the longitudinal axis of the eye is un-
affected. Furthermore, we find that exogenous glucagon slows
equatorial eye growth, resulting in smaller eyes, whereas glu-cagon receptor antagonists accelerate eye growth, resulting in
larger eyes. We also provide evidence that the bullwhip cells
selectively respond to growth-slowing and growth-accelerating
visual stimuli. Our findings indicate that a small population of
retinal neurons (b1000 per eye) can have a profound influence
on achieving proper organ size.
Materials and methods
Animals
The use of animals in these experiments was in accordance with the
guidelines established by the National Institutes of Health and The Ohio State
University. Newly hatched leghorn chickens (Gallus gallus domesticus) were
obtained from the Department of Animal Sciences at The Ohio State University
and kept on a cycle of 12 h light, 12 h dark (lights on at 7:00 am). Chicks were
housed in a stainless steel brooder at about 30 °C and received water and
Purina™ chick starter ad libitum.
Intraocular injections
Chickens were anesthetized by inhalation of 2.5% isoflurane in oxygen, as
described previously (Fischer et al., 1998b, 1999a,b). Injections were made
using a 25-μl Hamilton syringe and a 26-gauge needle with a beveled, curved
tip. Penetration of the needle was consistently made into the dorsal quadrant of
the vitreous chamber. In all experiments, 20 μl of vehicle containing the test
compound was injected into the experimental (left) eye, and 20 μl of vehicle
alone was injected into the control (right) eye. The vehicle was sterile saline
containing bovine serum albumin, 50 μg/ml, as carrier, and 5-bromo-2′-
deoxyuridine (BrdU; 100 μg/ml) to label proliferating cells. Test compounds
included colchicine (50–500 ng per dose; Sigma-Aldrich), recombinant human
glucagon (50–1000 ng per dose; Sigma-Aldrich), purified porcine glucagon-like
peptide 1 (GLP1; 200 ng per dose; Sigma-Aldrich), glucagon receptor anta-
gonists (des-His1, Phe6, Glu9-glucagon-NH2; 1000 ng per dose; Sigma-Aldrich)
or (2R)-N-[4-({4-(1-cyclohexen-1-yl)[(3,5-dichloroanilino)carbonyl]anilino}
methyl)benzoyl]-2-hydroxy-b-alanine (NNC 25-0926; 200–1000 ng per dose;
Novo Nordisk), recombinant human substance P (200 ng per dose; Sigma-
Aldrich), or apomorphine (200 ng per dose; Sigma-Aldrich).
Form-deprivation experiments
Chickens were form-deprived as described previously (Fischer et al.,
1998a,c, 1999b). We performed 3 separate experiments that involved form-
deprivation. Experiment 1: eight chickens at postnatal day 7 (P7) received
injections of 500 ng of colchicine into both eyes, as described above. Five days
later translucent plastic goggles were affixed, using gel Crazy-Glue™, to the
feathers surrounding the left eyes. The goggles were worn from P12 to P18, and
eyes were measured on P18. Experiment 2: eight chickens received goggles over
the left eyes at P4, goggles were removed at P9, and 2 h after the removal both
eyes were measured and retinas processed for immunolabeling. Experiment 3:
eight chickens received goggles at P8 and 24 h later both eyes were processed for
immunolabeling.
Reverse transcriptase PCR
Retina, choroid plus pigmented epithelium, and sclera from two P7 chickens
were isolated and placed in Trizol Reagent (∼50 mg tissue/700 μl Trizol;
Invitrogen). Total RNA was isolated according to the Trizol protocol and
resuspended in 50 μl RNAse free water. Genomic DNAwas removed by using
the DNA FREE kit provided by Ambion. cDNA was synthesized from mRNA
by using Superscript™ III First Strand Synthesis System (Invitrogen) and oligo
dT primers according to the manufacturer’s protocol. Control reactions were
performed using all components with the exception of the reverse transcriptase
to exclude the possibility that primers were amplifying genomic DNA.
PCR primers were designed by using the web-based program Primer 3 from
the Whitehead Institute for Biomedical Research (http://frodo.wi.mit.edu/cgi-
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receptor forward=5′ ACATCCACATGAACCTCTTCG 3′, glucagon receptor
reverse=5′ TAGTCCGTGTAGCGCATCTG 3′, GLP1 receptor reverse=5′ T-
GCCTCCACTACTGATGCTG 3′, and GLP1 receptor forward=5′ AAGAA-
TGCCTGTGGTGACAGT 3′. Predicted product sizes (in base pairs) were 620
(glucagon receptor), and 529 (GLP1 receptor). PCR reactions were performed
by using standard protocols, Platinum™ Taq (Invitrogen) and an Eppendorf
thermal cycler. PCR products were run on an agarose gel to verify the predicted
product sizes, TOPO-cloned (as described below) and sequenced to verify the
identity of the products.
TOPO cloning
PCR products were run on a 1.2% agarose gel, extracted and purified by
using Qiagen’s Qiaex II kit according to the manufacturer’s instructions. TOPO
cloning was performed using Invitrogen’s TOPO TA™ Cloning Kit and the
pCR-II vector according to manufacturer’s instructions.
In situ hybridization
Standard procedures were used for in situ hybridization as described
elsewhere (Fischer et al., 2002, 2004). In short, riboprobes were synthesized by
using a kit provided by Roche and stored at −80 °C until use. The anterior
segments of P7 eyes were dissected in RNAse-free Hanks Balanced Salt
Solution (HBSS), fixed for 2 h at room temperature in 4% paraformaldehyde
buffered in 0.1 M dibasic sodium phosphate, and embedded in OCT™. Cryo-
sections were processed for in situ hybridization with digoxigenin-labeled RNA
probes as described previously (Fischer et al., 2002, 2004). Negative controls
included hybridization of sense riboprobes and post-hybridization washes in
0.2× SSC at 70 °C. Hybridization was detected by using Fab fragments to
digoxygenin that were conjugated to alkaline phosphatase (anti-DIG-AP;
Roche) plus 10% normal goat serum, 10 mM levamisole, and 10 mM glycine in
MABT (0.05 M maleic acid buffer, 0.1% Tween-20). Ntiro-blue tetrazolium
(NBT) and 5-Bromo-4-Chloro-3′ Indolyphosphate p-Toluidine (BCIP) in 0.1 M
NaCl, 0.1 M Tris–HCl pH 9.5, 0.05 M MgCl2 and 0.01% Tween-20 were used
to precipitate chromophore from the anti-DIG-AP.
Fixation, sectioning and immunocytochemistry
Ocular tissues were fixed, sectioned and immunolabeled as described else-
where (Fischer et al., 1998b; Fischer and Stell, 1999). In short, enucleated eyes
were bisected across the equator and the gel vitreous removed from the posterior
eye cup. Posterior and anterior segments were fixed (4% paraformaldehyde plus
3% sucrose in 0.1 M phosphate buffer, pH 7.4, 30 min at 20 °C), washed three
times in PBS (phosphate-buffered saline; 0.05 M sodium phosphate, 195 mM
NaCl, pH 7.4), cryoprotected in PBS plus 30% sucrose, immersed in embedding
medium (OCT-compound; Tissue-Tek), and freeze-mounted onto sectioning
blocks. Transverse sections of the retina, nominally 12 μm thick, were cut from
different regions of the eye and mounted onto SuperFrost Plus™ slides (Fisher
Scientific). Sections from control and treated eyes from the same individual
were placed consecutively on each slide to ensure equal exposures to reagents.
Sections were air-dried and stored at −20 °C until use. Retinal whole-mounts
were processed for indirect immunofluorescence as described elsewhere
(Fischer et al., 2005, 2006).
Sections were thawed, ringed with rubber cement, washed three times in
PBS, covered with primary antibody solution (200 μl of antiserum diluted in
PBS plus 5% normal goat serum, 0.2% Triton X-100, and 0.01% NaN3), and
incubated for about 24 h at 20 °C in a humidified chamber. The slides were
washed three times in PBS, covered with secondary antibody solution, and
incubated for at least 1 h at 20 °C in a humidified chamber. Finally, samples were
washed three times in PBS, rubber cement removed from the slides, and
coverglasses mounted on 4:1 (v:v) glycerol to water.
Working dilutions and sources of antibodies used in this study included the
following. (i) Mouse anti-glucagon raised to full-length human glucagon was
used at 1:400 (Dr. M. Gregor, University of Tübingen via the Center for Ulcer
Research and Education, UCLA). (ii) Rabbit anti-GLP1 raised to amino acids 1–
19 of human GLP1 was used at 1:400 (4660-1604; Biogenesis Ltd.). (iii) Ratanti-substance P raised to full-length of human substance P conjugated to
bovine serum albumin was used at 1:400 (ab6338; Abcam). (iv) Mouse anti-
tyrosine hydroxylase raised to recombinant, full-length quail tyrosine
hydroxylase was used at 1:50 (αTH; Developmental Studies Hybridoma
Bank). (v) Mouse anti-Brn3a raised to amino acids 186–224 of mouse and used
at 1:200 (5A3.2; Chemicon). (vi) Mouse anti-neurofilament raised to bovine
NF-M was used at 1:2000 (RMO270, Dr. V. Lee, University of Pennsylvania).
(vii) Rabbit anti-cleaved caspase 3 (CC3) was raised to amino acids 163–175 of
human caspase 3 and used at 1:1000 (AF835; R&D Systems). (viii) Goat anti-
Egr1 raised to amino acids 282–433 of recombinant human Egr1 was used at
1:1000 (AF2818; R&D Systems). The amino acid sequence used to raise the
Egr1 antiserum is 88.2% identical to the chicken sequence, and the antibody
produced patterns of labeling that were identical to those reported previously
(Fischer et al., 1999a). Secondary antibodies included donkey-anti-goat-
Alexa488, goat-anti-rabbit-Alexa488, and goat-anti-mouse-Alexa488/568
(Molecular Probes Inc., Eugene, OR) diluted to 1:1000 in PBS plus 0.2%
Triton X-100.
Photography, measurements, cell counts, and statistical analyses
Photomicrographs were taken by using a Leica DM5000B microscope
equipped with epifluorescence and a 12 megapixel Leica DC500 digital
camera. Confocal microscopy was done by using a Ziess LSM 510 meta.
Images were optimized for color, brightness and contrast, and double-labeled
images overlaid by using Adobe Photoshop™6.0. Cell counts were made from
at least 5 different individuals, and means and standard errors calculated on
each data set. Counts of the bullwhip cells were made for the entire retina. To
avoid the possibility of region-specific differences within the retina, cell
counts were consistently made from the same region of retina for each data
set.
Measurements of eye size
The axial length of the eye was measured by using a 3.5 MHz A-scan
ultrasound (Zeiss). Photographs of enucleated eyes were taken using a 6.1
megapixel Nikon D100 SLR camera. High resolution digital images (N50
pixels/mm) of enucleated eyes were measured by using Image Pro Plus 6.2
(Mediacybernetics). Measurements obtained using Image Pro Plus 6.2 were
highly reproducible and had low levels of sampling error (±0.22%) at a
resolution of 50 pixels/mm or greater.
Results
Colchicine destroys bullwhip and mini-bullwhip cells when
applied at postnatal day 7
To assess the functions of the bullwhip and mini-bullwhip
cells we sought to identify a method by which to ablate these
cells. We tested whether the disruption of microtubules with
colchicine influenced the survival of the bullwhip cells. Deli-
very of colchicine into the vitreous chamber of newly hatched
(P0) chickens is known to destroy dopaminergic and glucago-
nergic amacrine cells, as well as most of the ganglion cells
(Fischer et al., 1999b; Morgan, 1981). However, the ability of
colchicine to destroy retinal ganglion cells is quickly reduced
during the early postnatal period (Morgan, 1981). The affects of
colchicine on the bullwhip and mini-bullwhip cells remain un-
known. Since these cells produce axon-like processes that form
numerous terminal arbors in the CMZ we hypothesized that the
bullwhip and mini-bullwhip cells may derive retrograde trophic
support from CMZ progenitors. Thus, the destruction of CMZ
progenitors and/or disruption of retrograde transport may affect
the survival of the bullwhip cells. In initial experiments, we
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eye at P2 and harvested retinas 11 days later. Compared to
saline-treated retinas (Figs. 1a and b), nearly all of the bullwhip
cells had been destroyed by colchicine-treatment (Figs. 1c, d
and g). In addition to the destruction of the bullwhip cells,
numerous ganglion cells and GACs were destroyed (Figs. 1c, d
and h), as reported previously (Fischer et al., 1999b). By con-
trast, a single intraocular injection of 50 ng colchicine at P7 did
not significantly compromise the survival of bullwhip cells and
GACs (Fig. 1g). However, 250 ng of colchicine destroyed
nearly 80% of the bullwhip cells (Fig. 1g), whereas the GACs
were left unaffected (data not shown). Similarly, 500 ng of
colchicine at P7 destroyed more that 95% of the bullwhip cells,
whereas numbers of GACs were not significantly reduced (Figs.
1e–h). The distribution of GAC somata and dendrites was not
influenced by 500 ng of colchicine in central or ventral regionsFig. 1. Colchicine destroys the bullwhip cells when applied at postnatal day 7 (P7). W
and photomicrographs obtained from central (a, c and e) and ventral (b, d and f) regio
and b), 500 ng colchicine at P2 (c and d), or 500 ng colchicine at P7. The calibration
bullwhip cells. Panel g is a histogram that shows the mean (±standard deviation) numb
P7. Panel h is a histogram that shows the mean (±standard deviation) number of gluc
colchicine at P2 of P7. ANOVAwas used to determine that there was significant (pb0
to determine the significance of difference (*pb0.0001) between saline- and colchicof the retina, where the bullwhip cells are normally found (Figs.
1e and f). Similarly, delivery of 500 ng of colchicine into the
vitreous chamber of P14 eyes resulted in the destruction of
N95% of the bullwhip cells, whereas the GACs were unaffected
(data not shown).
In dorsal–peripheral regions of the retina, we found that the
vast majority of mini-bullwhip cells were destroyed by col-
chicine-treatment at P7. Similar to the bullwhip cells, the mini-
bullwhip cells are immunoreactive for both glucagon and subs-
tance P (Fischer et al., 2006). The mini-bullwhip cells can be
easily distinguished from the smaller, conventional substance P-
expressing amacrine cells in whole-mount preparations of the
retina (Fischer et al., 2006). Compared to saline-treated retinas,
which contained numerous substance P-immunoreactive mini-
bullwhip cells and a dense agglomeration of neurites in the
CMZ (Figs. 2a and b), colchicine-treated retinas were depletedhole-mount preparations of the retina were labeled with antibodies to glucagon
ns of the retina. Retinas were obtained from eyes that were treated with saline (a
bar (100 μm) in panel f applies to panels a–f. The arrows indicate representative
er of bullwhip cells per retina from eyes treated with saline or colchicine at P2 or
agon-expressing amacrine cells (GACs) per mm2 in retinas treated with saline or
.0001) difference among treatment groups and a paired Student's t-test was used
ine-treated data sets.
Fig. 2. The mini-bullwhip cells and their terminals in the CMZ are destroyed by colchicine-treatment. Whole-mount preparations of control (a and b) and colchicine-
treated retinas (c–f) were labeled with antibodies to substance P. Images were made from peripheral (a, c and e) and far-peripheral (b, d and f) regions of the retina.
Arrows indicate mini-bullwhip cells and arrow-heads indicate conventional substance P-immunoreactive amacrine cells. The calibration bar (50 µm) in panel f applies
to all panels.
200 A.J. Fischer et al. / Developmental Biology 317 (2008) 196–212of mini-bullwhip cells, with the exception of a few (b10) cells
in far-nasal regions of the retina (Figs. 2c–f). With the loss of
the mini-bullwhip cells, we found a near-complete depletion of
substance P-immunoreactive neurites in the CMZ (Figs. 2d
and f). We occasionally found a few substance P-positive
neurites in nasal regions of the CMZ, close to the somata of
the mini-bullwhip cells that survived the colchicine-treatment
(Fig. 2f).
To assess whether the glucagon-immunoreactive neurites
that are clustered within the CMZ are depleted by colchicine we
immunolabeled transverse sections of the far periphery of
treated retinas. There was a near-complete absence of glucagon-
immunoreactive neurites in peripheral regions of the retina and
in the CMZ of colchicine-treated eyes (Figs. 3a–d). The gluca-
gon-immunoreactive neurites that are normally clustered within
the CMZ were ablated from all quadrants of the eye, with the
exception of a few processes that could occasionally be detected
in the nasal CMZ (Fig. 3d), consistent with observations of
substance P-immunoreactivity in whole-mount preparations of
colchicine-treated retinas. In addition, there was a significant
depletion of dopaminergic neurites, which were immunoreac-
tive for tyrosine hydroxylase (TH), in far-peripheral regions of
the retina within 600 μm of the CMZ (Figs. 3e–h). Furthermore,
there was a loss of ganglion cells that were immunoreactive for
Brn3a (Figs. 3i–l) and neurofilament (Figs. 3m–p) in far-
peripheral regions of colchicine-treated retinas. The loss ofganglion cells was more evident in temporal compared to nasal
regions of the peripheral retina, and these losses were confined
to within 700 μm of the CMZ.
To assess better whether colchicine ablated cells in addition
to the bullwhip and mini-bullwhip cells, we labeled whole-
mounts of treated retinas with antibodies to TH to identify the
dopaminergic amacrine cells and Brn3a to identify the ganglion
cells. The distribution of cell bodies and dendrites of the dopa-
minergic amacrine cells was not affected by colchicine-treat-
ment in any regions of the retina (Supplemental Figs. 1a–b),
with the exception of the far periphery (see Figs. 3f and h).
Ventral and central regions of colchicine-treated retinas con-
tained normal numbers of Brn3a-immunoreactive ganglion cells
(Supplemental Figs. 1c–j). By comparison, colchicine des-
troyed numerous Brn3a-positive ganglion cells in dorsal regions
of the retina (Supplemental Figs. 1c–j). Consistent with these
findings, we found that there was a depletion of DRAQ5-
labeled nuclei in the ganglion cell layer (GCL) in dorsal and far-
peripheral regions of colchicine-treated retinas (Supplemental
Fig. 2a). Similarly, in dorsal regions of colchicine-treated retinas
there was a depletion of ganglion cells that were immunore-
active for calretinin, Islet1, and RA4 (Supplemental Figs. 2b–
e). However, we failed to find evidence for the depletion of
amacrine cells (Islet1, calretinin, calbindin, TH), bipolar cells
(Islet1), horizontal cells (Islet1), or cones (calbindin, red–green
opsin) in dorsal regions of colchicine-treated retinas. For all
Fig. 3. Colchicine-treatment depletes the glucagon-immunoreactive neurites that are clustered within the CMZ, and destroys some retinal neurons in temporal regions
of the far-peripheral retina. Vertical sections of the retina were labeled with antibodies to glucagon (a–d), tyrosine hydroxylase (e–h), Brn3a (i–l) or neurofilament
(m–p). Double-ended arrows indicate the extent of the CMZ at the peripheral edge of the retina. The calibration bar (50 μm) in panel p applies to all panels.
Abbreviation: CMZ—circumferential marginal zone.
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chicine-treated retinas did not differ significantly from that in
control retinas (data not shown).
Our findings indicate that the survival of retinal neurons
(with the exception of the bullwhip cells) in central and ventral
regions of the retina is not compromised by colchicine-
treatment. These findings are consistent with previous reports
that the retinal ganglion cells are most sensitive to colchicine
during the first few postnatal days (Fischer et al., 1999b;
Morgan, 1981). Our data indicate that the ganglion cells in
dorsal and far-peripheral regions of the retina are destroyed by
colchicine-treatment at P7.Colchicine induces the apoptosis of retinal cells within 4 days
after treatment
To characterize better the retinal damage caused by colchi-
cine-treatment at P7 we applied antibodies to cleaved caspase 3
(CC3), to identify apoptotic cells, and the TUNEL method to
identify dying cells that contained fragmented DNA. In un-
treated retinas we failed to find cells that were immunoreactive
for CC3 (Fig. 4a). At 2 days after a single intraocular injection of
colchicine, we found a few scattered CC3-immunoreactive cells
in dorsal regions of the GCL (not shown). By comparison, there
were numerous CC3-immunoreactive cells in far-peripheral
Fig. 4. Colchicine-treatment at postnatal day 7 results in apoptosis of retinal neurons and progenitors in the CMZ. Tissues were obtained from saline-treated (control)
eyes (a and n), or at 2 (b–d), 3 (f–g), 4 days (h–m and o), or 5 days (p) after colchicine-treatment. Vertical sections were obtained from dorsal–central, nasal–peripheral
or temporal–peripheral regions of the retina. Sectionswere labeledwith antibodies to cleaved caspase 3 (CC3; a–m) and glucagon (n–p). Arrows indicatedCC3-positive
cells within the retina or CMZ (b–m), sprouted neurites (o′), or bullwhip cells that are degenerating (o and p). Double-ended arrows indicate the extent of the CMZ at the
peripheral edge of the retina. The calibration bar (50 μm) in panel i applies to panels f–i, the bar in panel m applies to panels a–e and panels j–m, the bar in panel o applies
to panels n and o, and the bar in panel p applies to panel p alone. Abbreviations: CC3—cleaved caspase 3, CMZ—circumferential marginal zone, ONL—outer nuclear
layer, INL—inner nuclear layer, IPL—inner plexiform layer, GCL—ganglion cell layer.
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CC3-immunoreactive cells in the CMZ in both temporal and
nasal regions of the retina (Figs. 4c and d). At 3 days after
colchicine-treatment, increased numbers of CC3-immunoreac-
tive cells were found in the GCL of dorsal regions of the retina
(Fig. 4e), in the GCL in far-peripheral regions of the retina, and
in the CMZ (Figs. 4f and g). By comparison, CC3-positive
cells were not found in ventral or far nasal regions of the retina
at 3 days after treatment (not shown). At 4 days after col-
chicine-treatment, numerous CC3-positive cells were observed
in the GCL in dorsal regions of the retina (Figs. 4h, l and m),
whereas few CC3-positive cells were observed in ventral
(Fig. 4k) and peripheral regions of the retina (Fig. 4i). At
5 days after treatment, few CC3-positive cells were observed
in dorsal or peripheral regions of the retina (data not shown).
To corroborate the findings of the immunolabeling for CC3,we used the TUNEL method to identify nuclei that contained
fragmented DNA. Our findings with TUNEL closely matched
those obtained by labeling for CC3. We found abundant
TUNEL-positive cells within the CMZ, in far-peripheral re-
gions of the INL, and in dorsal regions of the GCL bet-
ween 2 and 4 days after colchicine-treatment (Supplemental
Fig. 3).
We failed to find significant numbers of bullwhip and mini-
bullwhip cells that were CC3-positive (data not shown). How-
ever, we found numerous bullwhip cells that appeared to be
degenerating in colchicine-treated retinas. At 4 days after treat-
ment, most of the bullwhip cells sprouted numerous short pro-
cesses that extended away from the cell bodies (Figs. 4n and o).
By 5 days after treatment, most bullwhip cells had diminished
glucagon-immunoreactivity within their primary neurites. In
addition, the axons were fragmented, or truncated, and appeared
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after treatment, most bullwhip cells were no longer detectable
(data not shown).
In summary, colchicine-treatment at P7 destroyed the bull-
whip and mini-bullwhip cells, progenitors in the CMZ, some
neurons in far peripheral regions of the retina, and some gang-
lion cells in dorsal regions of the retina.
Colchicine-treatment at P7 results in increased equatorial eye
growth
We have reported previously that glucagon peptide is pro-
duced by the bullwhip cells, released from terminals clustered in
the CMZ, and acts to suppress the proliferation of retinal pro-
genitors (Fischer et al., 2005). Thus, colchicine-mediated abla-
tion of glucagon-positive neurites in the retinal periphery might
be expected to increase the proliferation of retinal progenitors in
the CMZ. To test this hypothesis, we made 5 consecutive daily
injections of BrdU (to label newly generated cells) into the
vitreous chamber of colchicine-treated eyes starting at 7 days
after treatment. We found that the ablation of glucagon-contain-
ing neurites within the CMZ did not increase numbers of BrdU-
labeled cells within far peripheral regions of the retina (data not
shown). This likely occurred because the colchicine destroyed
significant numbers of progenitors in the CMZ (see Fig. 4 and
Supplemental Fig. 3), and thereby reduced numbers of newly
generated, BrdU-labeled cells that are added to the edge of the
retina.
We have reported previously that colchicine-treatment on the
day of hatching results in increased rates of ocular growth and
axial elongation (Fischer et al., 1999b). Thus, we tested whether
colchicine-treatment at P7 influences the growth of the eye.
Unlike colchicine-treatment at P0, colchicine-treatment at P7
did not result in a significant increase in axial length; the dis-
tance from anterior cornea to posterior sclera (Figs. 5a, b and e).
However, the equatorial diameter and circumference of colchi-
cine-treated eyes were significantly larger than those in contra-
lateral control eyes (Figs. 5c, d and e). In contrast, the corneal
circumference was significantly smaller after colchicine-treat-
ment (Fig. 5e). The corneal radii of curvature in control and
colchicine-treated eyes were not significantly different (data not
shown).
The ablation of glucagon from the bullwhip and mini-
bullwhip cells may have resulted in increased rates of equatorial
growth in colchicine-treated eyes. To test this hypothesis we
injected both eyes with 500 ng colchicine at P7, and followed
this with daily injections of 50 ng of glucagon or vehicle at P12
through P17 and measured eye size at P18. There was no signi-
ficant difference in the axial length of colchicine-treated eyes
that received injections of saline compared to length of eyes that
received glucagon (Fig. 6a). By contrast, 50 ng doses of gluca-
gon significantly prevented the increases in equatorial diameter
and circumference resulting from colchicine-treatment (Fig.
6a). Colchicine-treated eyes that received injections of glucagon
were uniformly narrower (across both nasotemporal and dorso-
ventral planes) than eyes treated with colchicine followed by
injections of saline (Fig. 6a). The 50 ng injections of glucagondid not significantly affect colchicine-induced decreases in cor-
neal circumference.
At higher doses, glucagon completely prevented colchicine-
induced changes in ocular growth. Colchicine-damaged eyes
treated with 6 consecutive daily injections of 500 ng glucagon
were about 1 mm narrower in both the nasotemporal and
dorsoventral equatorial diameters compared to eyes that were
treated with colchicine and saline (Fig. 6b). This translated to a
3 mm decrease in the equatorial circumference (Fig. 6b). The
500 ng doses of glucagon did not influence the axial length of
colchicine-treated eyes, whereas the circumference of the
corneas of glucagon/colchicine-treated eyes was significantly
larger compared to that of saline/colchicine-treated eyes (Fig.
6b). The growth-suppressing effects of 50 ng doses of glucagon
were not as pronounced as those observed with 500 ng glucagon;
the 50 ng-effect was about 30% as large as the 500 ng-effect
(compare Figs. 6a and b). Interestingly, the equatorial circum-
ference of eyes treated with colchicine and 500 ng glucagon was
significantly (p=0.026; n=6) smaller than that of untreated
eyes; 40.71±0.87 mm versus 42.24±1.18 mm, respectively. By
comparison, the corneal circumference in eyes treated with col-
chicine and 500 ng glucagon was not significantly different (p=
0.78; n=6) than that of untreated eyes; 18.36±0.60 mm versus
18.47±0.68 mm, respectively.
Since the bullwhip cells, mini-bullwhip cells, and their
neurites within the CMZ are immunoreactive for GLP1 and
substance P (Fischer et al., 2005, 2006), either GLP1 or subs-
tance P (or both) could act in parallel to glucagon to regulate
equatorial eye growth. Accordingly, we made consecutive daily
intraocular injections of 200 ng of GLP1 or 200 ng of substance
P into colchicine-treated eyes. We found that the growth of eyes
treated with colchicine was not significantly affected by either
peptide (Figs. 6c and d).
Stone et al. (1989) reported that levels of retinal dopamine
are influenced by form-deprivation and that a dopamine recep-
tor agonist, apomorphine, inhibits the excessive ocular growth
that occurs with form-deprivation. Since dopaminergic cells
were depleted in far-peripheral regions of colchicine-treated
eyes (see Figs. 3e–h), it is possible that excessive equatorial
growth resulted from the depletion of dopamine near the
equator. Thus, we tested whether 6 consecutive daily intraocular
injections of 200 ng apomorphine inhibited colchicine-induced
expansion of the equator of the eye. This dose of apomorphine
has been shown to effectively inhibit form-deprivation-induced
axial elongation (Rohrer et al., 1993; Stone et al., 1989). We
found that the equatorial diameter and circumference of eyes
treated with colchicine and apomorphine were not significantly
different from those of the contralateral eyes that were treated
with colchicine and saline (Fig. 6e). However, apomorphine
caused a significant decrease in the axial length of colchicine-
treated eyes (Fig. 6e). These findings suggest that the activation
of dopamine receptors does not prevent colchicine-induced
equatorial eye growth, and that the dopaminergic cells in far-
peripheral regions of the retina are not responsible for regulating
equatorial eye size.
We have reported previously that colchicine-treatment at P0
destroys the retinal circuitry that promotes the excessive ocular
Fig. 5. Colchicine-treatment at P7 causes excessive growth around the equator of the eye, whereas there is no change in axial length. Eyes received a single intraocular
injection of colchicine at P7 and were measured at P18. Photographs of eyes were taken on axis (c and d) or across the plane of the equator (a and b). The calibration bar
(5 mm) in panel b applies to panels a and b, and the bar in panel d applies to panels c and d. The histogram in panel e illustrates the mean (±standard deviation)
difference (treated minus control; mm) for the axial length, nasotemporal diameter, dorsal–ventral diameter, equatorial circumference, and corneal circumference of
colchicine-treated eyes. The significance of difference (p-values) was determined by using a two-tailed, paired Student's t-test.
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may occur because P0 colchicine-treatment disrupts the retinal
cells and circuitry, namely the GACs, that regulate vision-guided
eye growth. Since P7 colchicine-treatment does not destroy the
GACs (see Fig. 1), we hypothesized that form-deprivation
would further increase rates of ocular growth in colchicine-
treated eyes. We found that form-deprived/colchicine-treated
eyes were significantly larger in axial length and equatorial di-
mensions compared to contra-lateral eyes that were treated with
colchicine alone (Fig. 6f). However, form-deprivation failed to
influence corneal circumference in the colchicine-treated eyes
(Fig. 6f).Glucagon and glucagon receptor antagonists influence the
equatorial growth of eyes with undamaged retinas
To assess whether glucagon influences the normal growth of
the eye, we made consecutive daily intraocular injections of
1 μg of glucagon from P6 through P11 and measured eyes at
P12. We found that axial length was unaffected by glucagon-
treatment (Fig. 7a). By contrast, the diameters across the naso-
temporal and dorsoventral equator of glucagon-treated eyes
were uniformly smaller, by about 0.5 mm, compared to the
diameters of control eyes. Accordingly, the equatorial circum-
ference of glucagon-treated eyes was N1 mm less than that of
Fig. 6. Glucagon suppresses the equatorial eye growth in colchicine-treated eyes, whereas form-deprivation accelerates eye growth and GLP1, substance P and
apomorphine have no effect. Both eyes were injected with 500 ng of colchicine at postnatal day (P7). Consecutive daily injections, beginning at P11 and ending at P17,
were made into the left eyes and eyes were measured at P18 (a–e). The right eyes were injected with vehicle as a control. Alternatively, eyes were treated with
colchicine at P7 and form-deprived from P11 through P17, and eyes measured at P18 (f). Compounds included 50 ng glucagon (a), 500 ng glucagon (b), 200 ng GLP1
(c), 200 ng substance P (d), or 200 ng apomorphine (e). Eye measurements included those for axial length, nasotemporal (N-T) equatorial diameter, dorsoventral (D-V)
equatorial diameter, equatorial circumference, and corneal circumference. The histograms provide data for the mean (n≥6) and standard deviation. Significance of
difference was determined by using a two-tailed, paired Student's t-test.
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7a). Exogenous glucagon had no significant affect upon corneal
diameter (Fig. 7a).
To assess whether the antagonism of glucagon receptors in-
fluences ocular growth we made injections of a glucagon pep-
tide antagonist (GPA), des-His1, Phe6, Glu9-glucagon-NH2. In
addition, we applied a novel glucagon receptor antagonist, NNC
25-0926, which has been shown to effectively block the activity
of glucagon in different biological systems (Lau et al., 2007;
Qureshi et al., 2004; Rivera et al., 2007). Intraocular injections
of 1000 ng GPA, 200 or 1000 ng of NNC 25-0926 were made
from P6 through P11 and eyes measured at P12. The GPA did
not significantly influence axial eye growth, whereas equatorial
growth was uniformly increased across both nasotemporal and
dorsoventral axes of the eye (Fig. 7b). The circumference of the
equator of GPA-treated eyes was about 0.8 mm greater than that
of contralateral control eyes (Fig. 7b). Interestingly, there was a
significant increase in the corneal circumference in eyes treated
with GPA (Fig. 7b). By contrast, 200 ng doses of NNC 25-0926
failed to significantly influence the size and shape of the eye
(Fig. 7c). However, a 5-fold greater daily dose of NNC 25-0926had significant affects upon ocular size and shape (Fig. 7d). We
found that the axial length of NNC 25-0926-treated eyes was
nearly 0.4 mm longer than that of contralateral control eyes
(Fig. 7d). Although the nasotemporal equatorial diameter of
NNC 25-0926-treated eyes was not significantly different from
controls, the dorsoventral equatorial diameter was significantly
increased and this was translated into a significant increase in
circumference (Fig. 7d). Corneal circumference was signifi-
cantly increased in eyes treated with 1000 ng of NNC 25-0926,
similar to eyes treated with GPA (Fig. 7d).
We failed to find evidence that the glucagon receptor anta-
gonists caused retinal damage or loss of bullwhip and mini-
bullwhip cells and their terminals in the CMZ (data not shown).
Consistent with our previous findings (Fischer et al., 2005), we
found that the GPA stimulated the addition of new cells to the
edge of the retina and non-pigmented epithelium (NPE) of the
ciliary body. Similarly, we found that the NNC 25-0926 stimu-
lated the addition of new cells to the edge of the retina and NPE
of the ciliary body (data not shown). Taken together, these
findings suggest that both the GPA and NNC 25-0926 do not
enhance eye growth by damaging the retina, and that these
Fig. 7. Glucagon inhibits the equatorial growth of the eye, whereas glucagon receptor antagonists stimulate equatorial growth. The left eyes of chickens were injected
daily with 1 μg of glucagon, 1 μg des-His1, Phe6, Glu9-glucagon-NH2 or (200 ng or 1 μg) glucagon receptor antagonist (NNC 25-0926) from P6 through P11, right
eyes received injections of saline, and eyes were measured at P12. The histograms provide data for the mean (n=6) and standard deviation. Significance of difference
was determined by using a two-tailed, paired Student's t-test.
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CMZ progenitors in addition to acting at extra-retinal sites.
The bullwhip cells respond to visual stimuli that regulate rates
of ocular growth
We have reported previously that the expression of the
immediate early gene Egr1 is up-regulated by GACs in response
to visual stimuli that slow rates of ocular growth (Fischer et al.,
1999a). By contrast, the GACs down-regulate Egr1 in response
to visual stimuli that accelerate rates of ocular growth. The
growth-accelerating visual stimuli included form-deprivation (a
light-diffusing goggle placed over the eye) and minus defocus
(imposed by a −7 diopter lens fitted over the eye). The growth-
slowing visual stimuli included plus defocus (imposed by a +7
diopter lens fitted over the eye) and unrestricted, normal vision
after 5 days of form-deprivation. Here we sought to assess
whether growth-regulating visual stimuli regulate the expres-
sion of Egr1 in the bullwhip cells.
In young chickens, form-deprivation is known to accelerate
rates of ocular growth and render eyes myopic (reviewed by
Wallman andWinawer, 2004). Here we confirmed that 5 days of
form-deprivation caused eyes to grow significantly larger and
more myopic than contralateral untreated eyes (data not shown).
After 24 h of form-deprivation, the majority of GACs were
negative for Egr1-immunoreactivity (data not shown), as des-
cribed previously (Fischer et al., 1999a). Similarly, form-depri-
vation for 24 h caused a significant reduction in the percentage
of bullwhip cells that expressed Egr1 (Figs. 8a–c and m). There
was a significant reduction in the percentage of bullwhip cellsthat expressed Egr1 compared to the percentage observed in
contra-lateral control retinas (Fig. 8m).
The “recovery” paradigm, in which a period of form-depri-
vation is followed by goggle-removal and unobstructed vision,
is an alternative method of rendering the eyes myopically
defocused. After 2 h of unrestricted vision following 5 days of
form-deprivation, the majority of GACs were immunoreactive
for Egr1 (Figs. 8d–f), consistent with previous reports (Bitzer
and Schaeffel, 2002; Fischer et al., 1999a). Here, Egr1 was
induced in more than 80% of the bullwhip cells after 5 days of
form-deprivation followed by 2 h of unobstructed vision, com-
pared to only about 25% after 5 days of continuously unobs-
tructed vision (Figs. 8g–i and m). Similar to previous reports
(Fischer et al., 1999a), we observed increased numbers of Egr1-
positive nuclei in the bipolar cell layer of the INL in retinas with
vision restored after 5 days of form-deprivation compared
numbers seen in control and form-deprived retinas (compare
Figs. 8a–c to d–i).
Receptors to glucagon and GLP1 are express by ocular tissues
in equatorial regions of the eye
We next sought to assess whether glucagon receptors are
expressed by the tissues that determine ocular shape and size.
By using RT-PCR we detected mRNA for the glucagon receptor
in the retina, choroid/RPE, and sclera (Fig. 9a). Similarly, we
detected mRNA for the GLP1 receptor in the retina and choroid/
RPE, and sclera (Fig. 9b). The PCR products were TOPO
cloned and sequenced to verify the specificity of the PCR re-
actions. To identify the cell types in the ocular tissues that
Fig. 8. Bullwhip cells respond to growth-slowing and growth-accelerating visual stimuli by up- or down-regulating Egr1, respectively. Vertical sections (a–i) and
whole-mounts (j–l) of the retina where labeled with antibodies to Egr1 (green) and glucagon (red). Retinas were obtained from eyes that were form-deprived for 24 h
(growth-accelerating) or form-deprived for 5 days followed by 2 h of normal vision (growth-slowing). Arrows indicate glucagon-positive amacrine cells or bullwhip
cells with nuclei that are labeled for Egr1, and arrow-heads indicate bullwhip cells that are negative for Egr1. The calibration bar (50 μm) in panel i applies to panels
a–i, and the bar in panel l applies to panels j–l. Panel m is a histogram illustrating the percentage of bullwhip cells that were immunoreactive for Egr1 in retinas from
eyes that were untreated (control), form-deprived for 24 h, or form-deprived for 5 days followed by 2 h of normal vision. Significance of difference was determined by
using ANOVA (pb0.0001) and a post-hoc Student's t-test; the p values are indicated in panel m. Bullwhip cells (n=466) were counted from at least 6 individuals from
sections and whole-mount preparations of the retina. Abbreviations: INL—inner nuclear layer, IPL—inner plexiform layer, FD—form-deprived.
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tion (ISH). Consistent with previous reports (Feldkaemper et al.,
2004; Fischer et al., 2005), we found ISH-signal for the
glucagon receptor within the retina, concentrated in the ONL,
proximal INL and GCL (Fig. 9c). The ISH-signal was present in
most photoreceptors, cells in the amacrine layers of the INL,
and cells in the GCL. At the peripheral edge of the retina,
mRNA for the glucagon receptor was detected within the CMZ,
the non-pigmented epithelium (NPE) of the ciliary body, and in
the ONL adjacent to the CMZ (Fig. 9d). The signal for the
glucagon receptor in the NPE extended through the pars plana
and into the pars plicata (Fig. 9e). Relatively little signal for theglucagon receptor was observed in the RPE and choroid. By
comparison, we observed ISH-labeling in the sclera. There was
relatively weak labeling in the cartilaginous sclera, whereas
labeling of greater intensity was observed in the fibrous sclera
(Figs. 9f and g). This labeling was present in the sclera that lies
behind peripheral (Fig. 9f) and central regions of the retina
(Supplemental Fig. 4a), and at the anterior edge of the cartila-
ginous sclera at the equator of the eye which lies near the peri-
pheral edge of the retina (Fig. 9g). Further, we observed robust
signal for the glucagon receptor in stromal and epithelial com-
partments of the corneal limbus, whereas weak ISH-signal for
the glucagon receptor was seen in the corneal epithelium and
Fig. 9. mRNA for glucagon receptor and GLP1 receptor are expressed by the
retina, choroid/RPE, and sclera in equatorial regions of the eye. mRNA was
detected by using reverse-transcriptase (RT) to generate pools of cDNA and PCR
with sequence-specific primers to glucagon receptor and GLP1 receptor. Total
RNAwas extracted and pooled from P7 retina and from choroid/RPE, whereas
RNA samples from sclera were keep separate for each individual. mRNA was
reverse transcribed into cDNA by using SuperScript III™ reverse transcriptase
(RT+), while control samples were reacted without enzyme (RT−). In situ
hybridization for mRNA coding for the glucagon receptor was performed on
sections of the retina (c), CMZ (d), pars plicata (e), peripheral sclera (f), anterior
edge of the cartilaginous sclera (g), and corneal limbus (h). The calibration bar
(50 μm) in panel d applies to panels c and d, the bar in panel g applies to panels
e–g, and the bar in panel h applies to panel h alone. Abbreviations: ONL—outer
nuclear layer, INL—inner nuclear layer, IPL—inner plexiform layer, GCL—
ganglion cell layer, CMZ—circumferential marginal zone, NPE—non-pigmen-
ted epithelium, fSCL—fibrous sclera, cSCL—cartilaginous sclera, Lim—
corneal limbus, epi—corneal epithelium, str—corneal stroma.
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to produce significant levels of labeling in all ocular tissues
(Supplemental Figs. 4b–e).
Discussion
Our findings indicate that the shape and size of a complex
organ, the eye, can be influenced by a relatively minor popu-
lation (b1000 cells) of intrinsic retinal neurons, the bullwhip
and mini-bullwhip cells. We find that colchicine destroys thevast majority of the glucagonergic bullwhip and mini-bullwhip
cells, as well as some retinal cells in far-peripheral and dorsal
regions of the retina, whereas the glucagon-containing amacrine
cells are unaffected. The colchicine-treated eyes grow exces-
sively around the equator, whereas corneal growth is suppressed
and axial eye length remains unaffected. Regardless of any
colchicine-mediated side-effects, exogenous glucagon comple-
tely inhibits the effects of colchicine-treatment on eye growth,
whereas GLP1, substance P and a dopamine receptor agonist
had no effect. This argues strongly that the depletion of gluca-
gon, due to the colchicine-mediated destruction of bullwhip and
mini-bullwhip, causes excessive equatorial eye growth in
colchicine-treated eyes.
We propose that glucagon, which is released from the term-
inals of the bullwhip and mini-bullwhip cells at the peripheral
edge of the retina, acts to slow equatorial eye growth. The overall
size and shape of the eye are determined by the growth and
remodeling of the sclera, the cartilaginous sheath of the eye
(reviewed by Rada et al., 1994;Wallman andWinawer, 2004).We
found that the depletion of glucagon-releasing terminals from the
edge of the retina and the application of glucagon receptor anta-
gonists caused excessive growth around the equator of the eye.
Consistent with these findings, intraocular injections of glucagon
suppressed equatorial eye growth in normal eyes and in eyes
lacking bullwhip cells. Our data indicate that axial and equatorial
eye growth can occur independently and are regulated by different
retinal cell types. Colchicine-treatment at P7 did not ablate the
CAGs, and axial eye length was normal, whereas equatorial
growth was increased. In addition, form-deprivation caused axial
and equatorial ocular enlargement of colchicine-treated eyes,
where the bullwhip and mini-bullwhip cells were ablated and the
CAGs remained intact. These findings suggest that the retinal
circuitry and cells, namely the CAGs, that permit accelerated axial
eye growth in response to degraded image contrast are unaffected
by colchicine-treatment at P7. Thus, we propose that axial eye
length is regulated by the CAGs and equatorial growth is
regulated by the bullwhip and mini-bullwhip cells.
Consistent with the hypothesis that retinal glucagon regu-
lates the growth of the ocular equator and cornea, we found that
glucagon receptors are widely expressed by anterior ocular
tissues. Glucagon receptor mRNAwas detected at the peripheral
edge of the retina, in the NPE of the ciliary body, the sclera and
the corneal limbus. We propose that these glucagon receptors
are normally activated by glucagon that is produced by retinal
neurons. The only sources of glucagon peptide within the eye
are the GACs, bullwhip cells and mini-bullwhip cells. Never-
theless, it is possible that systemic glucagon, produced by
pancreatic cells, acts at receptors in the eye to influence overall
growth. However, it seems unlikely that pancreas-derived glu-
cagon participates in vision-guided ocular growth. Thus, we
propose that glucagon peptide that is released from the terminals
of the bullwhip and mini-bullwhip cells at the peripheral edge of
the retina could act on the fibrous or cartilaginous sclera to
influence equatorial eye growth, as well as corneal growth. See
Fig. 10 for a schematic summary.
Although reducing glucagon-signaling significantly increased
equatorial scleral growth, at the same time corneal growth (cir-
Fig. 10. Schematic diagram describing the proposed progression of events by which visual stimuli, glucagon and bullwhip cells regulate the equatorial growth of the
eye and cornea. The red arrows indicate the release and dissemination of glucagon peptide from terminals that are clustered in the CMZ. The black arrows indicate the
relative direction of change in eye shape in response to growth-guiding visual stimuli and glucagon release. Panel a illustrates the relative position of the bullwhip cells
and glucagon-releasing terminal in the CMZ to the equatorial sclera and cornea. Panel b summarizes the effects of growth-enhancing visual stimuli on the bullwhip
cells, glucagon release, and eye growth. Panel c summarizes the effects of growth-inhibiting visual stimuli on the bullwhip cells, glucagon release, and eye growth.
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corneal and scleral growth are regulated independently, at least
in part. The mechanisms underlying the reduced corneal growth
in colchicine-treated eyes remain uncertain. It is possible that
intravitreal delivery of colchicine destroyed the corneal limbal
stem cells, which in turn suppressed normal corneal growth.
Alternatively, glucagon that is released from the terminals of the
bullwhip and mini-bullwhip cells at the periphery of the retina
may normally stimulate corneal growth. This would require that
glucagon peptide diffuses from the peripheral edge of the retina
out to the corneal limbus. In support of this possibility, we found
that intravitreal delivery of glucagon peptide blocked colchi-
cine-mediated decreases in corneal circumference. However,
glucagon had no affect on corneal circumference in eyes with
undamaged retinas, and the glucagon receptor antagonists
increased corneal diameter in eyes with undamaged retinas. It
remains uncertain how corneal circumference is differentially
regulated by glucagon receptor agonist and antagonists in
normal and colchicine-treated eyes. We propose that there may
be coordination of retina-derived signals with the growth of the
cornea during postnatal development. Similarly, the embryoniceye relies heavily on reciprocal interactions of the optic vesicle/
cup (prospective retina) with the overlying ectoderm (prospec-
tive lens and cornea) for proper ocular development (reviewed
by Chow and Lang, 2001).
The reported effects of glucagon and receptor antagonists on
ocular growth have been inconsistent. Vessey and colleagues
have reported that injections of glucagon or glucagon antagonist
(des-Phe6-glucagon-NH2) do not influence the normal axial
growth of eyes with unrestricted vision (Vessey et al., 2005a).
The authors proposed that the glucagon antagonist is not en-
tirely effective at chicken glucagon receptors and that the glu-
cagon peptide did not influence ocular growth because the
endogenous growth-suppressing signals are already near or at
saturation. The study by Vessey and colleagues used 5 con-
secutive daily intraocular injections of nearly 700 ng of gluca-
gon or antagonist to open eyes, but failed to find significant
changes in refractive error or axial length. It remains possible
that glucagon and glucagon receptor antagonist influenced
equatorial eye growth, but these changes went unmeasured
(W.K. Stell, personal communication). We found that 6 conse-
cutive daily intraocular injections of 1000 ng glucagon sup-
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affected. In line with these observations, we found that 5 con-
secutive daily injections of 1000 ng des-His1, Phe6, Glu9-
glucagon-NH2 failed to influence axial eye growth, whereas
equatorial eye growth was increased. Similarly, a small mole-
cular inhibitor of the glucagon receptor NNC 25-0926 caused
increases in axial length and equatorial diameter. The growth
enhancing effects of NNC 25-0926 were pronounced across the
dorsoventral equatorial axis. This lipophilic compound was in-
jected consistently into the dorsal quadrant of the eye and, thus,
may have preferentially influenced the growth of dorsal equa-
torial regions of the eye. The subtle differences in the effects of
the glucagon receptor antagonists upon axial and equatorial
growth may reflect differences in the efficacy and/or ability of
these compounds to diffuse within the eye and avoid clearance
and degradation.
Similar to the GACs, the bullwhip cells respond to growth-
regulating visual stimuli. Form-deprivation prevents clear
images from being projected onto the retina; insufficient image
contrast fails to activate the retinal circuitry to halt eye growth
(reviewed by Wallman and Winawer, 2004). In the postnatal
chicken, the deprivation of clear vision or minus defocus causes
a down-regulation in the expression of Egr1 in the GACs
(Fischer et al., 1999a). Conversely, growth-halting visual stimuli
such as plus-defocus or restoration of clear vision after form-
deprivation stimulate the expression of Egr1 in the GACs
(Fischer et al., 1999a). We report here that the bullwhip cells up-
or down-regulate Egr1 in response to growth-slowing or growth-
accelerating visual stimuli, respectively. However, it should be
noted that the bullwhip cells are a distinctly different type of cell
compared to the GACs; with different morphologies, neuro-
transmitters, and immunohistochemical profiles (Fischer et al.,
2006). Despite these differences, it seems likely that both the
bullwhip cells and GACs participate in the retinal circuitry that
detects image defocus to regulate eye size and shape. We pro-
pose that growth-regulating visual stimuli, acting through inter-
mediate retinal circuitry, regulate the activity of bullwhip cells
and thereby the rate of release of glucagon at the retinal margin.
This results in either increased glucagon release, which retards
equatorial eye growth; or decreased glucagon release, which
allows equatorial eye growth to continue unimpeded. Similarly,
reduced release of glucagon from the terminals of the bullwhip
and mini-bullwhip cells may allow for increased proliferation
of progenitors in the CMZ (Fischer et al., 2005). Taken
together, our findings may explain why CMZ progenitors
proliferate at increased rates in form-deprived eyes (Fischer
and Reh, 2000). We propose that bullwhip cells are relatively
inactive during form-deprivation, and consequently the rate
of glucagon release is relatively low. Therefore, in form-
deprived eyes the proliferation-suppressing influence of
glucagon is relieved, and the progenitors proliferate at
increased rates. Vision-regulated release of glucagon from the
terminals of the bullwhip and mini-bullwhip may coordinate
the growth of the retina, equatorial growth of the sclera, and
circumferential growth of the cornea. This proposed mechan-
ism of regulating retinal and equatorial eye growth is illustrated
in Fig. 10.Colchicine treatment at P7 caused some cell death within the
CMZ, indicating that colchicine destroyed some of the proli-
ferating progenitors. Colchicine is known to cause M-phase
arrest, and this, in turn, can lead to cell death (reviewed by
Downing, 2000). The loss of CMZ progenitors may have, se-
condarily, caused the loss of bullwhip cells. We have suggested
elsewhere that the bullwhip cells require trophic support from
target cells to survive (Fischer et al., 2005, 2006, 2007). Thus, it
is possible that colchicine-mediated death of CMZ progenitors
depletes the bullwhip cells of trophic support, and thereby
causes the death of the bullwhip cells. Additionally, colchicine
may disrupt the microtubules in the axons of the bullwhip cells,
thereby preventing retrograde transport of trophic signals back to
the cell bodies. Colchicine is known to prevent the retrograde
axonal transport of trophic cues and attenuate the survival of
many different types of projection neurons (reviewed by Avila,
1992).
The GACs, dopaminergic amacrine cells, and the majority of
ganglion cells are sensitive to colchicine shortly after hatching,
before P2. However, these cell types become tolerant to colchi-
cine-treatment shortly after early stages of postnatal retinal de-
velopment, with the exception of the ganglion cells in far-
peripheral and dorsal regions of the retina. It is likely that the
ganglion cells that remain sensitive to colchicine at P7 are rela-
tively immature. Ganglion cells are known to be first generated
in central–ventral regions of the retina, whereas the ganglion
cells in dorsal and peripheral regions of retina are generated
about 3 days later (Kahn, 1973, 1974; Prada et al., 1991). Si-
milarly, far-peripheral regions of the chicken retina are gene-
rated late during embryonic development, between E12 and
E16, with nasal regions being generated before temporal re-
gions (Ghai et al., 2008). We propose that the immaturity of
neurons in far temporal regions of the retina renders these cells
more susceptible to colchicine-induced cell death compared to
the more mature cells in far nasal regions of the retina. Sen-
sitivity to colchicine may be manifested through active remo-
deling of microtubules, which are prevalent in maturing neurons
(Black, 1994; Kobayashi and Mundel, 1998).
Conclusions
Despite any colchicine-mediated side-effects upon retinal
cells in addition to the bullwhip and mini-bullwhip cells, re-
placement of glucagon peptide into treated eyes completely
prevented changes in eye shape and size that resulted from
colchicine-treatment. In colchicine-treated eyes, glucagon pep-
tide is depleted because of the destruction of bullwhip and mini-
bullwhip cells and their terminals at the far-peripheral edge of
the retina. Because the terminals of bullwhip and mini-bullwhip
cells are concentrated near the equator of the eye, it seems
logical that one function of the glucagon that they release is to
restrict scleral growth at the equator. We conclude that the
bullwhip and mini-bullwhip cells, despite their modest
numbers, have a profound influence on the shape and size of
the eye. We propose that the bullwhip and mini-bullwhip cells,
like the conventional glucagon-expressing amacrine cells, are
part of the retinal circuitry that detects image defocus; these
211A.J. Fischer et al. / Developmental Biology 317 (2008) 196–212defocus cues are used by the bullwhip and mini-bullwhip cells
to precisely regulate the equatorial growth of the eye, the retina
and, possibly, corneal circumference.
Acknowledgments
We thank Drs. Heithem M. El-Hodiri, Don Mutti, Stuart
Mangel and William K. Stell for comments that contributed to
the final form of this paper. We thank Drs. Virginia Lee, Paul
Linser, and Steve McLoon for providing antibodies to neuro-
filament, 2M6, and RA4, respectively. Expert technical assist-
ance with confocal microscopy was provided at the Campus
Microscopy and Imaging Facility at The Ohio State University.
The tyrosine hydroxylase antibody, developed by Drs. Le Doua-
rin and Ziller, was obtained from the Developmental Studies
Hybridoma Bank developed under auspices of the NICHD and
maintained by the University of Iowa, Department of Biological
Sciences, Iowa City, IA 52242. This work was supported by a
grant (#0413795) from the National Science Foundation award-
ed to AJF.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ydbio.2008.02.023.
References
Avila, J., 1992. Microtubule functions. Life Sci. 50, 327–334.
Bitzer, M., Schaeffel, F., 2002. Defocus-induced changes in ZENK expression
in the chicken retina. Invest. Ophthalmol. Visual Sci. 43, 246–252.
Black, M.M., 1994. Microtubule transport and assembly cooperate to generate
the microtubule array of growing axons. Prog. Brain. Res. 102, 61–77.
Chow, R.L., Lang, R.A., 2001. Early eye development in vertebrates. Annu.
Rev. Cell Dev. Biol. 17, 255–296.
Del Rio-Tsonis, K., Tsonis, P.A., 2003. Eye regeneration at the molecular age.
Dev. Dyn. 226, 211–224.
Downing, K.H., 2000. Structural basis for the interaction of tubulin with
proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell Dev.
Biol. 16, 89–111.
Ehrlich, D., Keyser, K.T., Karten, H.J., 1987. Distribution of substance P-like
immunoreactive retinal ganglion cells and their pattern of termination in the
optic tectum of chick (Gallus gallus). J. Comp. Neurol. 266, 220–233.
Feldkaemper, M.P., Schaeffel, F., 2002. Evidence for a potential role of
glucagon during eye growth regulation in chicks. Vis. Neurosci. 19,
755–766.
Feldkaemper, M.P., Burkhardt, E., Schaeffel, F., 2004. Localization and
regulation of glucagon receptors in the chick eye and preproglucagon
and glucagon receptor expression in the mouse eye. Exp. Eye Res. 79,
321–329.
Fischer, A.J., 2005. Neural regeneration in the chick retina. Prog. Retin. Eye
Res. 24, 161–182.
Fischer, A.J., Reh, T.A., 2000. Identification of a proliferating marginal zone of
retinal progenitors in postnatal chickens. Dev. Biol. 220, 197–210.
Fischer, A.J., Reh, T.A., 2003. Growth factors induce neurogenesis in the ciliary
body. Dev. Biol. 259, 225–240.
Fischer, A.J., Stell, W.K., 1999. Nitric oxide synthase-containing cells in the
retina, pigmented epithelium, choroid, and sclera of the chick eye. J. Comp.
Neurol. 405, 1–14.
Fischer, A.J., Miethke, P., Morgan, I.G., Stell, W.K., 1998a. Cholinergic
amacrine cells are not required for the progression and atropine-mediated
suppression of form-deprivation myopia. Brain Res. 794, 48–60.Fischer, A.J., Seltner, R.L., Poon, J., Stell, W.K., 1998b. Immunocytochemical
characterization of quisqualic acid- and N-methyl-D-aspartate-induced
excitotoxicity in the retina of chicks. J. Comp. Neurol. 393, 1–15.
Fischer, A.J., Seltner, R.L., Stell, W.K., 1998c. Opiate and N-methyl-D-aspartate
receptors in form-deprivation myopia. Vis. Neurosci. 15, 1089–1096.
Fischer, A.J., McGuire, J.J., Schaeffel, F., Stell, W.K., 1999a. Light- and focus-
dependent expression of the transcription factor ZENK in the chick retina.
Nat. Neurosci. 2, 706–712.
Fischer, A.J., Morgan, I.G., Stell, W.K., 1999b. Colchicine causes excessive
ocular growth and myopia in chicks. Vis. Res. 39, 685–697.
Fischer, A.J., Dierks, B.D., Reh, T.A., 2002. Exogenous growth factors induce
the production of ganglion cells at the retinal margin. Development 129,
2283–2291.
Fischer, A.J., Omar, G., Eubanks, J., McGuire, C.R., Dierks, B.D., Reh, T.A.,
2004. Different aspects of gliosis in retinal Muller glia can be induced
by CNTF, insulin and FGF2 in the absence of damage. Mol. Vis. 10,
973–986.
Fischer, A.J., Omar, G., Walton, N.A., Verrill, T.A., Unson, C.G., 2005.
Glucagon-expressing neurons within the retina regulate the proliferation of
neural progenitors in the circumferential marginal zone of the avian eye.
J. Neurosci. 25, 10157–10166.
Fischer, A.J., Skorupa, D., Schonberg, D.L., Walton, N.A., 2006. Characteriza-
tion of glucagon-expressing neurons in the chicken retina. J. Comp. Neurol.
496, 479–494.
Fischer, A.J., Stanke, J.J., Ghai, K., Scott, M., Omar, G., 2007. Development of
bullwhip neurons in the embryonic chicken retina. J. Comp. Neurol. 503,
538–549.
Ghai, K., Stanke, J.J., Fischer, A.J., 2008. Patterning of the circumferential
marginal zone of progenitors in the chicken retina. Brain Res. 1192, 76–89.
Kahn, A.J., 1973. Ganglion cell formation in the chick neural retina. Brain Res.
63, 285–290.
Kahn, A.J., 1974. An autoradiographic analysis of the time of appearance of
neurons in the developing chick neural retina. Dev. Biol. 38, 30–40.
Kobayashi, N., Mundel, P., 1998. A role of microtubules during the formation of
cell processes in neuronal and non-neuronal cells. Cell Tissue Res. 291,
163–174.
Lau, J., Behrens, C., Sidelmann, U.G., Knudsen, L.B., Lundt, B., Sams, C.,
Ynddal, L., Brand, C.L., Pridal, L., Ling, A., Kiel, D., Plewe, M., Shi, S.,
Madsen, P., 2007. New beta-alanine derivatives are orally available gluca-
gon receptor antagonists. J. Med. Chem. 50, 113–128.
Morgan, I.G., 1981. Intraocular colchicine selectively destroys immature gang-
lion cells in chicken retina. Neurosci. Lett. 24, 255–260.
Moshiri, A., McGuire, C.R., Reh, T.A., 2005. Sonic hedgehog regulates pro-
liferation of the retinal ciliary marginal zone in posthatch chicks. Dev. Dyn.
233, 66–75.
Otteson, D.C., Hitchcock, P.F., 2003. Stem cells in the teleost retina: persistent
neurogenesis and injury-induced regeneration. Vis. Res. 43, 927–936.
Prada, C., Puga, J., Perez-Mendez, L., Lopez, R., Ramirez, G., 1991. Spatial and
temporal patterns of neurogenesis in the chick retina. Eur. J. Neurosci. 3,
559–569.
Qureshi, S.A., Rios Candelore, M., Xie, D., Yang, X., Tota, L.M., Ding, V.D.,
Li, Z., Bansal, A., Miller, C., Cohen, S.M., Jiang, G., Brady, E., Saperstein,
R., Duffy, J.L., Tata, J.R., Chapman, K.T., Moller, D.E., Zhang, B.B., 2004.
A novel glucagon receptor antagonist inhibits glucagon-mediated biological
effects. Diabetes 53, 3267–3273.
Rada, J.A., Matthews, A.L., Brenza, H., 1994. Regional proteoglycan
synthesis in the sclera of experimentally myopic chicks. Exp. Eye Res. 59,
747–760.
Rada, J.A., Shelton, S., Norton, T.T., 2006. The sclera and myopia. Exp. Eye
Res. 82, 185–200.
Raymond, P.A., Hitchcock, P.F., 1997. Retinal regeneration: common principles
but a diversity of mechanisms. Adv. Neurol. 72, 171–184.
Raymond, P.A., Hitchcock, P.F., 2000. How the neural retina regenerates.
Results Probl. Cell Differ. 31, 197–218.
Reh, T.A., Levine, E.M., 1998. Multipotential stem cells and progenitors in the
vertebrate retina. J. Neurobiol. 36, 206–220.
Rivera, N., Everett-Grueter, C.A., Edgerton, D.S., Rodewald, T., Neal, D.W.,
Nishimura, E., Larsen, M.O., Jacobsen, L.O., Kristensen, K., Brand, C.L.,
212 A.J. Fischer et al. / Developmental Biology 317 (2008) 196–212Cherrington, A.D., 2007. A novel glucagon receptor antagonist, NNC 25-
0926, blunts hepatic glucose production in the conscious dog. J. Pharmacol.
Exp. Ther. 321, 743–752.
Rohrer, B., Spira, A.W., Stell, W.K., 1993. Apomorphine blocks form-depri-
vation myopia in chickens by a dopamine D2-receptor mechanism acting in
retina or pigmented epithelium. Vis. Neurosci. 10, 447–453.
Stone, R.A., Lin, T., Laties, A.M., Iuvone, P.M., 1989. Retinal dopamine and
form-deprivation myopia. Proc. Natl. Acad. Sci. U. S. A. 86, 704–706.
Vessey, K.A., Lencses, K.A., Rushforth, D.A., Hruby, V.J., Stell, W.K., 2005a.Glucagon receptor agonists and antagonists affect the growth of the chick
eye: a role for glucagonergic regulation of emmetropization? Invest. Oph-
thalmol. Visual Sci. 46, 3922–3931.
Vessey, K.A., Rushforth, D.A., Stell, W.K., 2005b. Glucagon- and secretin-
related peptides differentially alter ocular growth and the development of
form-deprivation myopia in chicks. Invest. Ophthalmol. Visual Sci. 46,
3932–3942.
Wallman, J., Winawer, J., 2004. Homeostasis of eye growth and the question of
myopia. Neuron 43, 447–468.
